Cataract Surgery Cost & Access, Country by Country
The price of restoring sight ranges from a few dollars to a few thousand — and the gap has almost nothing to do with the operation. It is about volume, supply chains, and the cost of a tray of consumables.
The 60-second brief
- Cataract is the leading cause of avoidable blindness worldwide[1][3] — and fully reversible with surgery.
- Access is measured by the Cataract Surgical Rate (surgeries per million/year); many Global-South countries fall far short of the ~3,000 needed to hold the backlog.
- Cost is driven less by surgeon time than by consumables — IOL, viscoelastic, stain — which recur on every eye.
- Affordable, quality-made Indian consumables are the reason many programmes can afford to scale.
Access is a rate, not a promise
Every country can point to a hospital that does excellent cataract surgery. That is not the same as access. Access is a rate — how many operations a health system delivers per million people each year, against how many new cataracts appear. That single figure, the Cataract Surgical Rate, separates countries clearing their backlog from those falling behind[2].
When the CSR sits below the incidence of new operable cataract, the queue grows even as surgeons work flat out. Raising it is not primarily a clinical problem — it is a logistics and economics problem. More trained surgeons, yes; but above all, more surgeries per surgeon per day, and a consumable supply that is cheap and reliable enough to sustain that volume.
The cost & access map
Cost and access cluster by region. Below, the picture across the markets where demand for affordable, quality cataract supply is rising fastest.
Nigeria · Kenya · Tanzania · Uganda · Zimbabwe · Botswana · Rwanda · Senegal · Togo · Sudan · Somalia · Tunisia · Algeria
Much of Sub-Saharan Africa runs CSRs far below target, with outreach camps doing the heavy lifting. Surgery is often subsidised or free at point of care through NGOs and public programmes, which makes the consumable cost per eye the decisive budget line. Reliable, low-cost viscoelastic, stain and IOL supply is what lets a visiting team operate on 40–60 eyes in a single camp day without running short.
Brazil · Peru · Bolivia · Paraguay · Uruguay · Honduras · Nicaragua · Panama · Costa Rica · Cuba · Dominican Republic · Guyana · Trinidad & Tobago · Bahamas
Latin America pairs strong surgical centres with deep rural gaps. National campaigns have shown the region can clear backlog quickly when IOLs and consumables are affordable and reliably stocked. Public-programme budgets — and therefore how many patients get reached each year — turn directly on the price of the tray.
India · Vietnam · Philippines · Cambodia · Maldives · Timor-Leste · Mongolia
The largest backlog and the proven solution sit side by side. India delivers world-benchmark outcomes at a fraction of Western cost[4]; Vietnam, the Philippines and Cambodia are scaling fast and increasingly source consumables and lenses from Indian manufacturers who hit the price point without compromising sterility or optics.
Samoa · Tonga · Solomon Islands · Lebanon · Serbia · Belarus
Small, remote systems depend entirely on imported, shelf-stable consumables and IOLs. Long shelf life and simple storage are as important as price, because every case rides on an air-freighted supply chain that cannot fail mid-mission.
What actually sets the price
Strip a cataract case to its costs and the list is short. Surgeon time and theatre overhead scale with efficiency; consumables scale with every eye. That is why the consumable line dominates any serious conversation about access.
Illustrative relative weighting, not a price list. The point stands regardless of exact figures: consumables recur per eye, so their price is the throttle on national volume.
The multiplier
Halve the consumable cost and a fixed budget reaches 2× the patients.
This is the whole logic of affordable eye care. Skill scales through training; machines are a one-time cost; but consumables are paid again on every eye — so their price decides how many people a country can un-blind this year.
What the data actually says
Global estimates for 2020 put roughly 43 million people living with blindness and about 295 million with moderate-to-severe vision impairment; cataract is the single leading cause of that blindness, accounting for close to 45% of cases[3]. And the pressure is rising, not falling: as populations age, the number of people needing cataract surgery is projected to climb steeply through 2050, so a country standing still is quietly falling behind.
This is where the Cataract Surgical Rate becomes concrete. India now runs a CSR well above 6,000 operations per million per year; several high-income systems sit around 8,000–11,000. Much of Sub-Saharan Africa, by contrast, still operates below 1,000–2,000 — often not even keeping pace with new cases, let alone reducing the backlog[2]. Two countries with identical disease burden can therefore have completely different blindness outcomes purely because one clears its queue and the other does not.
Access has a fourth enemy that budgets often miss: demand. In many rural districts, people with dense cataracts simply do not present — because of cost fear, distance, lack of awareness, or the belief that blindness is an unavoidable part of ageing. A programme can have surgeons, theatres and cheap consumables and still fail if patients never reach the door. Sustainable access needs all four pillars at once: trained surgeons, high-throughput systems, affordable consumables, and active demand generation.
The budget maths, made explicit
Consider a public programme with a fixed annual consumables budget of, say, US$150,000 — a realistic order of magnitude for a district eye-care initiative. Suppose the consumable cost per case (IOL + viscoelastic + stain + antibiotic + sundries) lands at about US$25 with efficient sourcing.
| Consumable cost / case | Cases funded by US$150,000 | Patients still waiting (of 10,000) |
|---|---|---|
| US$50 (premium imports) | 3,000 | 7,000 |
| US$35 | 4,285 | 5,715 |
| US$25 (affordable quality) | 6,000 | 4,000 |
Same budget, same surgeons, same theatres — double the patients reached simply by halving the consumable cost, with no compromise in the quality of the lens or viscoelastic used. This is not a rhetorical flourish; it is the arithmetic that governs every national blindness-control programme on earth. It is also why the choice of supplier is a public-health decision, not a procurement footnote[4].
Figures are illustrative to show the mechanism; real per-case costs and budgets vary by market, lens type and procurement scale.
References & peer-reviewed sources
- World Health Organization. Blindness and vision impairment — Fact sheet. www.who.int/news-room/fact-sheets/detail/blind…
- IAPB. Vision Atlas — Magnitude & projections of vision loss. www.iapb.org/learn/vision-atlas/magnitude-and-…
- GBD Vision Loss Expert Group. Causes of blindness & vision impairment in 2020. Lancet Glob Health 2021;9:e144–e160. doi.org/10.1016/S2214-109X(20)30489-7…
- Aravind Eye Care System. High-volume, high-quality cataract care & the cross-subsidy model. www.aravind.org/our-story/…
- Gogate PM, Kulkarni SR, et al. RCT phaco vs MSICS. Ophthalmology 2007;114:965–968. pubmed.ncbi.nlm.nih.gov/17217857/…
The solutions behind the surgery
The consumables that make affordable, high-volume cataract surgery possible — viscoelastics, stains, intracameral agents and IOLs, built for camp days and busy public theatres.
Explore the full range on the Agaaz product portfolio.
Access is a supply-chain problem. We build the supply.
Programmes, hospitals and distributors across Africa, Latin America, Asia and the Pacific partner with Agaaz for consumables and IOLs that keep cataract care affordable.
Cataract Surgery Cost & Access, Country by Country
The price of restoring sight ranges from a few dollars to a few thousand — and the gap has almost nothing to do with the operation. It is about volume, supply chains, and the cost of a tray of consumables.
The 60-second brief
- Cataract is the leading cause of avoidable blindness worldwide[1][3] — and fully reversible with surgery.
- Access is measured by the Cataract Surgical Rate (surgeries per million/year); many Global-South countries fall far short of the ~3,000 needed to hold the backlog.
- Cost is driven less by surgeon time than by consumables — IOL, viscoelastic, stain — which recur on every eye.
- Affordable, quality-made Indian consumables are the reason many programmes can afford to scale.
Access is a rate, not a promise
Every country can point to a hospital that does excellent cataract surgery. That is not the same as access. Access is a rate — how many operations a health system delivers per million people each year, against how many new cataracts appear. That single figure, the Cataract Surgical Rate, separates countries clearing their backlog from those falling behind[2].
When the CSR sits below the incidence of new operable cataract, the queue grows even as surgeons work flat out. Raising it is not primarily a clinical problem — it is a logistics and economics problem. More trained surgeons, yes; but above all, more surgeries per surgeon per day, and a consumable supply that is cheap and reliable enough to sustain that volume.
The cost & access map
Cost and access cluster by region. Below, the picture across the markets where demand for affordable, quality cataract supply is rising fastest.
Nigeria · Kenya · Tanzania · Uganda · Zimbabwe · Botswana · Rwanda · Senegal · Togo · Sudan · Somalia · Tunisia · Algeria
Much of Sub-Saharan Africa runs CSRs far below target, with outreach camps doing the heavy lifting. Surgery is often subsidised or free at point of care through NGOs and public programmes, which makes the consumable cost per eye the decisive budget line. Reliable, low-cost viscoelastic, stain and IOL supply is what lets a visiting team operate on 40–60 eyes in a single camp day without running short.
Brazil · Peru · Bolivia · Paraguay · Uruguay · Honduras · Nicaragua · Panama · Costa Rica · Cuba · Dominican Republic · Guyana · Trinidad & Tobago · Bahamas
Latin America pairs strong surgical centres with deep rural gaps. National campaigns have shown the region can clear backlog quickly when IOLs and consumables are affordable and reliably stocked. Public-programme budgets — and therefore how many patients get reached each year — turn directly on the price of the tray.
India · Vietnam · Philippines · Cambodia · Maldives · Timor-Leste · Mongolia
The largest backlog and the proven solution sit side by side. India delivers world-benchmark outcomes at a fraction of Western cost[4]; Vietnam, the Philippines and Cambodia are scaling fast and increasingly source consumables and lenses from Indian manufacturers who hit the price point without compromising sterility or optics.
Samoa · Tonga · Solomon Islands · Lebanon · Serbia · Belarus
Small, remote systems depend entirely on imported, shelf-stable consumables and IOLs. Long shelf life and simple storage are as important as price, because every case rides on an air-freighted supply chain that cannot fail mid-mission.
What actually sets the price
Strip a cataract case to its costs and the list is short. Surgeon time and theatre overhead scale with efficiency; consumables scale with every eye. That is why the consumable line dominates any serious conversation about access.
Illustrative relative weighting, not a price list. The point stands regardless of exact figures: consumables recur per eye, so their price is the throttle on national volume.
The multiplier
Halve the consumable cost and a fixed budget reaches 2× the patients.
This is the whole logic of affordable eye care. Skill scales through training; machines are a one-time cost; but consumables are paid again on every eye — so their price decides how many people a country can un-blind this year.
What the data actually says
Global estimates for 2020 put roughly 43 million people living with blindness and about 295 million with moderate-to-severe vision impairment; cataract is the single leading cause of that blindness, accounting for close to 45% of cases[3]. And the pressure is rising, not falling: as populations age, the number of people needing cataract surgery is projected to climb steeply through 2050, so a country standing still is quietly falling behind.
This is where the Cataract Surgical Rate becomes concrete. India now runs a CSR well above 6,000 operations per million per year; several high-income systems sit around 8,000–11,000. Much of Sub-Saharan Africa, by contrast, still operates below 1,000–2,000 — often not even keeping pace with new cases, let alone reducing the backlog[2]. Two countries with identical disease burden can therefore have completely different blindness outcomes purely because one clears its queue and the other does not.
Access has a fourth enemy that budgets often miss: demand. In many rural districts, people with dense cataracts simply do not present — because of cost fear, distance, lack of awareness, or the belief that blindness is an unavoidable part of ageing. A programme can have surgeons, theatres and cheap consumables and still fail if patients never reach the door. Sustainable access needs all four pillars at once: trained surgeons, high-throughput systems, affordable consumables, and active demand generation.
The budget maths, made explicit
Consider a public programme with a fixed annual consumables budget of, say, US$150,000 — a realistic order of magnitude for a district eye-care initiative. Suppose the consumable cost per case (IOL + viscoelastic + stain + antibiotic + sundries) lands at about US$25 with efficient sourcing.
| Consumable cost / case | Cases funded by US$150,000 | Patients still waiting (of 10,000) |
|---|---|---|
| US$50 (premium imports) | 3,000 | 7,000 |
| US$35 | 4,285 | 5,715 |
| US$25 (affordable quality) | 6,000 | 4,000 |
Same budget, same surgeons, same theatres — double the patients reached simply by halving the consumable cost, with no compromise in the quality of the lens or viscoelastic used. This is not a rhetorical flourish; it is the arithmetic that governs every national blindness-control programme on earth. It is also why the choice of supplier is a public-health decision, not a procurement footnote[4].
Figures are illustrative to show the mechanism; real per-case costs and budgets vary by market, lens type and procurement scale.
References & peer-reviewed sources
- World Health Organization. Blindness and vision impairment — Fact sheet. www.who.int/news-room/fact-sheets/detail/blind…
- IAPB. Vision Atlas — Magnitude & projections of vision loss. www.iapb.org/learn/vision-atlas/magnitude-and-…
- GBD Vision Loss Expert Group. Causes of blindness & vision impairment in 2020. Lancet Glob Health 2021;9:e144–e160. doi.org/10.1016/S2214-109X(20)30489-7…
- Aravind Eye Care System. High-volume, high-quality cataract care & the cross-subsidy model. www.aravind.org/our-story/…
- Gogate PM, Kulkarni SR, et al. RCT phaco vs MSICS. Ophthalmology 2007;114:965–968. pubmed.ncbi.nlm.nih.gov/17217857/…
The solutions behind the surgery
The consumables that make affordable, high-volume cataract surgery possible — viscoelastics, stains, intracameral agents and IOLs, built for camp days and busy public theatres.
Explore the full range on the Agaaz product portfolio.
Access is a supply-chain problem. We build the supply.
Programmes, hospitals and distributors across Africa, Latin America, Asia and the Pacific partner with Agaaz for consumables and IOLs that keep cataract care affordable.
Start writing here...
Cataract Surgery Cost & Access Across Africa, Asia & Latin America: The 2026 Country Guide